Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.88 |
| ▸ | CA1 | P00915 | 14/20 | 0.88 |
| ▸ | CA9 | Q16790 | 13/20 | 0.88 |
| ▸ | CA12 | O43570 | 12/20 | 0.88 |
| ▸ | MAOA | P21397 | 2/20 | 0.68 |
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | CA4 | P22748 | 4/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27578396 | 0.98 | CA2 (0.84) | CA2CA1CA9CA12MAOA | |
| SCHEMBL27888182 | 0.88 | CA1 (0.71) | CA2CA1CA9CA12MAOA | |
| SCHEMBL6725859 | 0.85 | CA2 (0.77) | CA2CA1CA9CA12MAOA | |
| SCHEMBL17459406 | 0.84 | CA2 (0.64) | CA2CA1CA9CA12MAOA | |
| SCHEMBL18361661 | 0.84 | CA1 (0.65) | CA2CA1CA9CA12MAOA | |
| SCHEMBL8652656 | 0.82 | PTGS2 (0.72) | CA2CA1CA9CA12MAOA | |
| SCHEMBL671898 | 0.82 | CA12 (1.00) | CA2CA1CA9CA12MAOA | |
| SCHEMBL8974236 | 0.82 | CA2 (0.72) | CA2CA1CA9CA12MAOA | |
| SCHEMBL6721732 | 0.81 | CA12 (0.70) | CA2CA1CA9CA12MAOA | |
| SCHEMBL8514633 | 0.80 | CA2 (0.59) | CA2CA1CA9CA12MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119528773-A | N-alkylation method of sulfonamide compound | 赣南医科大学 | 2025-02-28 | — | — | CN | claimed |
| CN-119219810-A | Ionic polymer and preparation method and application thereof | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-118685793-A | Synthesis method of thio-N-heterocyclic compound | 南阳师范学院 | 2024-09-24 | — | — | CN | claimed |
| CN-114614058-B | Thin-layer composite proton exchange membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-116396193-A | Method for preparing alpha-sulfonamido acetals from fatty aldehydes and sulfonamides | 西北工业大学 | 2023-07-07 | — | — | CN | claimed |
| CN-114432903-B | Composite membrane with acid resistance and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-114614058-A | Thin-layer composite proton exchange membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-114432903-A | Composite membrane with acid resistance and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| WO-2013028574-A2 | AQUEOUS LITHIUM AIR BATTERIES | POLYPLUS BATTERY COMPANY (US) | 2013-02-28 | — | — | WO | claimed |
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | US | claimed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| US-20260049084-A1 | ENPP1 MODULATORS AND PRODUCTS AND USES THEREOF | GOSSAMER BIO SERVICES INC (US) | 2026-02-19 | — | — | US | disclosed |
| CN-119528773-A | N-alkylation method of sulfonamide compound | 赣南医科大学 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025011551-A1 | MODIFIED POLYVINYLIDENE FLUORIDE AND PREPARATION METHOD THEREFOR, ACTIVE MATERIAL COMPOSITION, POSITIVE ELECTRODE SHEET, AND ENERGY STORAGE DEVICE | 深圳海辰储能科技有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-20250019371-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-01-16 | — | — | US | disclosed |
| US-5276184-A | Curing agents for epoxy resins for thermosetting resins | THE DOW CHEMICAL COMPANY (US) | 1994-01-04 | — | — | US | disclosed |
| US-5235008-A | Curable | THE DOW CHEMICAL COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
| EP-0478918-A2 | Adducts of epoxy resins and active hydrogen containing compounds containing mesogenic moieties | THE DOW CHEMICAL COMPANY (US) | 1992-04-08 | — | — | EP | disclosed |
| EP-0469492-A2 | Polymer modified adducts of epoxy resins and active hydrogen containing compounds containing mesogenic moieties | THE DOW CHEMICAL COMPANY (US) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270383-A1 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | KCNH1, RYR1, CACNA1E | CA2 2459/4885CA1 2914/4885CA9 4398/4885 |
| US-20260049084-A1 | ENPP1 MODULATORS AND PRODUCTS AND USES THEREOF | ENPP1, PPP1R1B, PHLPP1 | CA2 526/4885CA1 2010/4885CA9 916/4885 |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | CA2 307/4885CA1 2057/4885CA9 3338/4885 |
| US-20250019371-A1 | SMALL-MOLECULAR INHIBITORS FOR THE BETA-CATENIN/ B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | CA2 4582/4885CA1 4388/4885CA9 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.